SUBOXONE Film from Indivior PLC - longseller for opioid dependence with once-daily dosing

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 08:58. Details in the imprint.

SUBOXONE Film from Indivior PLC does not look like a typical medicine at first glance. You place the thin orange strip under your tongue, it softens against the warm saliva and sticks like a wafer, slowly releasing active substance instead of a quick swallow-and-forget tablet.

How SUBOXONE Film works

SUBOXONE Film combines buprenorphine, a partial opioid agonist, with naloxone, an opioid antagonist, in a single sublingual formulation for maintenance treatment of opioid dependence. The naloxone component is intended to deter misuse by injection, because it can precipitate withdrawal if the product is used parenterally.

According to Indivior, the film is indicated as part of a comprehensive treatment plan that includes counseling and psychosocial support, not as a stand-alone solution.Official SUBOXONE product information from Indivior Prescribers are instructed to stabilize patients on measured buprenorphine doses and then adjust gradually, watching for cravings and withdrawal signs.

Daily use in the clinic

On the ward, addiction specialist Dr. Sarah Mitchell describes the routine as almost ritual: the nurse hands over the foil pouch, the patient peels it open with slightly shaking fingers and slides the strip under the tongue, then sits quietly for several minutes while it dissolves and a faint citrus taste lingers in the mouth.

The film is designed to deliver once-daily dosing with strengths typically ranging from 2 mg/0.5 mg to 8 mg/2 mg of buprenorphine/naloxone, allowing titration across a range of dependence severities.U.S. prescribing information for SUBOXONE Film For many clinics, the strip format simplifies supervision compared with loose tablets, because staff can see that the dose has gone into the mouth rather than a pocket.

Why the film format matters

For patients, the tactile feel of the strip between tongue and palate can be a quiet reminder that this is a controlled, measured step away from chaotic street opioids rather than another pill to chase with water. The design also allows printing of dose strength on the film itself, which helps reduce confusion in multi-dose regimens.Clinical overview of buprenorphine-naloxone film formulations

Clinicians often highlight that the sublingual route bypasses first-pass metabolism in the liver, improving buprenorphine bioavailability and supporting steady plasma levels across the day. At the same time, careful patient education is needed so the strip is not chewed or swallowed too early, which would reduce effectiveness and might frustrate people in withdrawal.

Strengths and limitations

SUBOXONE Film's main strength is consistency: the product has been on the U.S. market for more than a decade, with a large body of clinical experience and familiarity among addiction professionals. Dosing can be individualized, but the routine feels predictable, which helps build trust between doctor and patient.

The limitations are equally clear. As a controlled substance, buprenorphine carries diversion risk; regulators and Indivior have faced scrutiny over marketing practices and stewardship of the product in vulnerable populations. Some patients dislike the taste or the waiting time while the strip dissolves, preferring newer depot injections even if those require monthly clinic visits.

Place in Indivior's portfolio

For Indivior PLC, SUBOXONE Film sits alongside newer formulations such as SUBLOCADE, an extended-release buprenorphine injection, but remains a central revenue driver in many regions, especially where long-acting injectables are not yet widely reimbursed. Management repeatedly stresses the role of the film as an accessible entry point to medication-assisted treatment, particularly in community settings.

All told, Indivior PLC shares (ISIN GB00BYZ0C031) trade primarily on the London Stock Exchange, with the SUBOXONE franchise continuing to underpin a significant portion of group sales in the core U.S. market.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.